Cytokinetics
CYTK
108 hedge funds and large institutions have $366M invested in Cytokinetics in 2017 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 35 increasing their positions, 29 reducing their positions, and 16 closing their positions.
591% more call options, than puts
Call options by funds: $4.32M | Put options by funds: $626K
75% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 16
21% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 29
13% more capital invested
Capital invested by funds: $323M → $366M (+$42.7M)
7% more funds holding
Funds holding: 101 → 108 (+7)
2.73% more ownership
Funds ownership: 65.48% → 68.21% (+2.7%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$35.5M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$5.34M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$3.91M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.13M |
| 5 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
+$2.51M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$6.91M |
| 2 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$2.56M |
| 3 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$2.09M |
| 4 |
GC
Globeflex Capital
San Diego,
California
|
-$1.69M |
| 5 |
CCMH
Cornerstone Capital Management Holdings
New York
|
-$1.1M |
CYTK Hedge Fund Activity: Q1 2017 in Review
108 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Cytokinetics (CYTK) for Q1 2017, worth a combined $366M — up 13% from $323M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new CYTK positions and 16 closed out — a net gain of 12 holders — while 35 added to existing stakes and 29 trimmed.
The largest buyer was BlackRock, adding an estimated $35.5M. The largest seller was BVF Inc, cutting an estimated $6.91M.
- 108 institutional investors held Cytokinetics (CYTK) as of Q1 2017, up from 101 in Q4 2016.
- Funds reported $366M of Cytokinetics stock for Q1 2017, up 13% quarter-over-quarter.
- 28 funds opened new Cytokinetics positions in Q1 2017 and 16 closed out, a net change of +12 holders.
- The largest Cytokinetics buyer in Q1 2017 was BlackRock, an estimated $35.5M added.
- The largest Cytokinetics seller in Q1 2017 was BVF Inc, an estimated $6.91M sold.
Based on aggregated 13F filings for Q1 2017.